The WES and RAN-seq will be performed to identify and verify neoantigens and appropriate mRNA sequences will be verified, manufactured and protected for vaccine production by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the mRNA vaccine for immunotherapy of human cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the mRNA vaccine immunotherapy on human cancers will firstly be evaluated.

开始日期2024-05-08

申办/合作机构

广州医科大学附属第二医院

100 项与 Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University) 相关的临床结果

登录后查看更多信息

100 项与 Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University) 相关的转化医学

登录后查看更多信息

100 项与 Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University) 相关的专利（医药）

登录后查看更多信息

项与 Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University) 相关的文献（医药）

2024-10-11·Science Advances

Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity

Article

作者: Huang, Lei ; Wang, Qiuhe ; Tang, Dean G. ; Xu, Zhuya ; Liang, Shujing ; Zhong, Zhixian ; Xu, Mingcheng ; Dong, Chunyan ; Ren, Jiale ; Yang, Jingxian ; Xu, Congcong ; Wu, Jichuan ; Jamroze, Anmbreen ; Shen, Haifa ; Fan, Ting ; Zhu, Zhounan ; Chen, Chunxiu ; Tang, Yuying ; Zhu, Hanfei ; Cai, Yihua ; Ma, Xiaopin ; Yu, Bo ; Chen, Fengjia ; Li, Qianyun ; Cao, Wanlu ; Zhang, Mingna ; Li, Hangwen

mRNA neoantigen cancer vaccine inducing neoantigen-specific T cell responses holds great promise for cancer immunotherapy; however, its clinical translation remains challenging because of suboptimal neoantigen prediction accuracy and low delivery efficiency, which compromise the in vivo therapeutic efficacy. We present a lipopolyplex (LPP)–formulated mRNA cancer vaccine encoding tandem neoantigens as a cancer therapeutic regimen. The LPP-formulated mRNA vaccines elicited robust neoantigen-specific CD8 + T cell responses in three syngeneic murine tumor models (CT26, MC38, and B16F10) to suppress tumor growth. Prophylactic cancer vaccine treatment completely prevented tumor development, and long-lasting memory T cells protected mice from tumor cell rechallenge. Combining the vaccine with immune checkpoint inhibitor further boosted the antitumor activity. Of note, LPP-based personalized cancer vaccine was administered in two cancer patients and induced meaningful neoantigen-specific T cell and clinical responses. In conclusion, we demonstrated that the LPP-based mRNA vaccine can elicit strong antitumor immune responses, and the results support further clinical evaluation of the therapeutic mRNA cancer vaccine.

2024-04-01·Med

Melanoma neoantigen vaccines: Are we getting more personal now?

Article

作者: Haanen, John B ; Latifyan, Sofiya

KEYNOTE-942¹ is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain.

2024-03-01·Nature Reviews Clinical Oncology

Personalized neoantigen mRNA vaccine mitigates melanoma recurrence

Article

作者: Killock, David

100 项与 Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University) 相关的药物交易

登录后查看更多信息